Workflow
Nuwellis(NUWE)
icon
Search documents
Nuwellis Adds Nationally Ranked Utah Hospital as New Pediatric Customer for Aquadex SmartFlow® Therapy
GlobeNewswire· 2025-01-13 13:00
MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, is pleased to announce its newest pediatric hospital customer, a nationally ranked hospital in Utah. The hospital, Nuwellis’ 44th pediatric account, will be utilizing the Aquadex SmartFlow® system to treat children suffering from fluid overload caused by kidney and heart disease. Since 2020 when the FDA granted clearance, Nuwellis has inc ...
Nuwellis Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire News Room· 2024-12-19 14:00
MINNEAPOLIS, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (the “Company” or “Nuwellis”) today announced that the Company received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq’s stockholders’ equity requirement (“Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1). The Company's Co ...
Nuwellis(NUWE) - 2024 Q3 - Quarterly Report
2024-11-12 21:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-35312 NUWELLIS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware No. 68-0533453 (State or Oth ...
Nuwellis(NUWE) - 2024 Q3 - Quarterly Results
2024-11-12 12:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Nuwellis, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification No.) Delaware 001-35312 No. 68-0533453 12988 Valley View Road, Eden Prairie, MN (Address ...
Nuwellis(NUWE) - 2024 Q3 - Earnings Call Transcript
2024-11-11 16:02
Nuwellis, Inc. (NASDAQ:NUWE) Q3 2024 Earnings Call Transcript November 11, 2024 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO John Jefferies - CMO Rob Scott - CFO Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good day, everyone, and Welcome to Nuwellis’ Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during th ...
Nuwellis, Inc. (NUWE) Q3 Earnings Surpass Estimates
ZACKS· 2024-11-11 15:15
Nuwellis, Inc. (NUWE) came out with quarterly earnings of $1.74 per share, beating the Zacks Consensus Estimate of a loss of $0.88 per share. This compares to loss of $63.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 297.73%. A quarter ago, it was expected that this company would post a loss of $9.49 per share when it actually produced a loss of $18.85, delivering a surprise of -98.63%.Over the last four quarters, the com ...
Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire News Room· 2024-11-11 13:00
MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights: Received a 297% CMS reimbursement increase to $1,639 for Aquadex facility fee, effective January 1, 2025.Revenue of $2.4 million.Pediatrics revenue growth of 28% compared to the prior year quarter.Gross margin of 70%, compared to 57.3% in the p ...
Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds
GlobeNewswire News Room· 2024-11-05 14:28
MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company’s common stock at their current exerc ...
Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid
GlobeNewswire News Room· 2024-11-04 13:30
Reimbursement rate to increase 397% per day effective January 1, 2025 New rate expected to encourage adoption of ultrafiltration therapy in the outpatient setting MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) will reassign the Aquadex ultrafiltration code to the outpatient reimbursement le ...
Nuwellis Announces Preliminary Results for Third Quarter of 2024
GlobeNewswire News Room· 2024-11-01 20:15
MINNEAPOLIS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company dedicated to transforming the lives of patients suffering from fluid overload, today announced certain preliminary, unaudited results for the quarter ended September 30, 2024. The company plans to report its complete results and host its earnings conference call for the third quarter of 2024 on November 11, 2024. Based on preliminary, unaudited results, management expects the Company to report the followin ...